Neurobehavioral Medicine Group | ClinicalTrials HQ

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD	attention deficit hyperactivity disorder, inattentive type, neurodevelopmental disorder, oppositional defiant disorder, psychiatric disorder	Recruiting	Phase 4	2026-10-05		NCT04781140
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients	Irritability Associated With Autism Spectrum Disorder	Recruiting	Phase 3	2026-09-25		NCT06706674
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients	Bipolar and Related Disorders, bipolar disorder, mood disorder, psychiatric disorder	Recruiting	Phase 3	2026-09-25		NCT06372964
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder	Bipolar and Related Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, autism spectrum disorder, bipolar disorder, mood disorder, neurodevelopmental disorder, pervasive developmental disorder, psychiatric disorder, schizophrenia	Recruiting	Phase 3	2026-09-25		NCT06229210
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)	Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy	Recruiting	Phase 3	2026-09-16		NCT07011732
ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)	autism, autism spectrum disorder, neurodevelopmental disorder, pervasive developmental disorder, psychiatric disorder	Active, not recruiting	Phase 2	2026-07-20		NCT05889273